INTRODUCTION
Rosai-Dorfman disease, also called sinus histiocytosis with massive lymphadenopathy, is a rare histiocytic condition of unknown etiology first described in 1969. 1 Primary cutaneous manifestation without systemic involvement of Rosai-Dorfman disease is even more uncommon. 2 Here we present a case of primary cutaneous manifestation of Rosai-Dorfman disease with excellent response to oral thalidomide.
CASE REPORT
A 49-year-old African-American woman initially presented with a 6-year history of an eruption on the lower extremities. She did not report systemic symptoms in association with this eruption. On physical examination, the patient had scattered violaceous-to-pink firm nodules overlying indurated plaques within hyperpigmented patches on the medial right lower leg (Fig 1, A) and medial left thigh. The patient did not have any lymphadenopathy. An excisional biopsy from the right leg found histiocytic proliferation with emperipolesis ( Fig 2) . Immunohistochemical staining of the histiocytes showed positive stain for S100, CD68, CD20, CD3, and CD30 and negative stain for CD1a and langerin. These findings were most consistent with a non-Langerhans cell histiocytosis, specifically Rosai-Dorfman disease.
The patient was initially treated with intralesional triamcinolone (20 mg/mL) to the nodules on legs and fluocinonide 0.5% cream to all the affected areas. Because of poor response, she was referred to the radiation oncology department and subsequently treated with 20 fractionated radiation doses, 40 Gy total, with minimal improvement. She was subsequently treated with methotrexate (15 mg weekly) but did not respond. Thalidomide, 50 mg nightly, was started and increased to 100 mg nightly. The methotrexate was slowly tapered and discontinued. After 5 months of treatment, the nodules on the patient's thigh and lower leg showed a noticeable improvement in erythema with decrease in size (Fig 1, B) . The patient was taking thalidomide, 100 mg nightly, with no relapse of the disease process at her 9-month follow-up visit. The patient did report more fatigue with the increased dose of thalidomide.
DISCUSSION
Rosai-Dorfman disease is a rare, generally benign and self-limited condition that primarily presents as painless, cervical lymphadenopathy accompanied by fever, neutrophilia, polyclonal hypergammaglobulinemia, and elevated erythrocyte sedimentation rate (ESR). 3 Cutaneous Rosai-Dorfman disease is characterized by nonspecific macules, papules, plaques, or nodules of variable color. Because of the nonspecific skin findings, biopsy is critical to diagnosis, which reveals a hallmark characteristic of emperipolesis or histiocytes with lymphocytes within their cytoplasm. The histiocytes stain positive for S-100 and CD68 and negative for CD1a and langerin. 4 Because cutaneous Rosai-Dorfman disease usually follows a benign course, treatment is generally not indicated unless there is extensive involvement, if the condition persists, or if the patient is significantly affected by disease. There are several treatments described in the literature for cutaneous Rosai-Dorfman disease, including methotrexate, chemotherapy, surgery, and steroids. 4-9 Li et al 5 described successful resolution of cutaneous Rosai-Dorfman disease with lowdose thalidomide of 100 mg. Our patient did not respond to intralesional triamcinolone, topical corticosteroids, radiation therapy, and methotrexate over 3 years but responded well to thalidomide. We conducted a literature review of the successful and failed cases of thalidomide for treatment of cutaneous Rosai-Dorfman disease. Data gathered for 7 patients from 5 publications are presented in Table I .
The review consisted of 3 men and 4 women. The ages ranged from 41 to 72 years, with an average age for presentation of 53.1 years. The average duration of disease before diagnosis was 7.6 months. Five of the 7 cases had a negative or unavailable medical history; 1 patient had mild anemia, bilateral uveitis, elevated ESR, and IgG hypergammaglobulinemia, 10 whereas another had elevated ESR and polyclonal hypergammaglobulinemia. 6 Five patients did not respond to multiple treatments before starting thalidomide. Five of the 7 cases reported improvement with thalidomide, whereas 2 cases had minimal response. Of the cases that reported response to thalidomide, only 2 cases used low-dose thalidomide. 5, 12 It is not precisely known how thalidomide works, but the drug is used for several cutaneous conditions because of its immune-modulating and antiinflammatory effects. Thalidomide decreases the CD4:CD8 ratio in patients with erythema nodosum leprosum. 14 Thalidomide also affects chemotaxis of polymorphonuclear leukocytes and phagocytosis through cytokine alterations and inhibits tumor necrosis factor-a. 14 It has antitumor properties and in vitro effects of converting a T-helper cell type 1 to a T-helper cell type 2 response. 14 Thalidomide is effective in treating several dermatologic conditions, including chronic graft-versus-host disease, cutaneous lupus erythematosus, recurrent aphthous stomatitis, and Behçet's disease. 14 Moreover, thalidomide is documented as a treatment for histiocytic disorders. There are cases of purely cutaneous, lowrisk Langerhans cell histiocytosis effectively treated with thalidomide. 15, 16 Thalidomide was also found to be effective in treating vulvar Langerhans cell histiocytosis. 17 Side effects reported from thalidomide use include peripheral neuropathy, pulmonary toxicity, neutropenia, somnolence, and constipation. 14, 16 Our patient did not note peripheral neurologic symptoms, but she noted a decreased sense of taste 5 months after starting therapy as well as fatigue.
Cutaneous Rosai-Dorfman disease is a rare condition that does not have a consensus treatment, although several treatment options are available. Thalidomide, both low and high doses, was found to be an effective treatment in some cases. However, further investigation is needed to understand why thalidomide works in some patients and not in others as well as the ideal dosage for pediatric and adult patients and optimal duration for thalidomide treatment. These questions would be best addressed in a 
